David Schiff

32.8k total citations · 4 hit papers
373 papers, 16.9k citations indexed

About

David Schiff is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Neurology. According to data from OpenAlex, David Schiff has authored 373 papers receiving a total of 16.9k indexed citations (citations by other indexed papers that have themselves been cited), including 201 papers in Genetics, 109 papers in Pulmonary and Respiratory Medicine and 78 papers in Neurology. Recurrent topics in David Schiff's work include Glioma Diagnosis and Treatment (199 papers), Brain Metastases and Treatment (81 papers) and Meningioma and schwannoma management (40 papers). David Schiff is often cited by papers focused on Glioma Diagnosis and Treatment (199 papers), Brain Metastases and Treatment (81 papers) and Meningioma and schwannoma management (40 papers). David Schiff collaborates with scholars based in United States, Canada and Germany. David Schiff's co-authors include Patrick Y. Wen, Timothy F. Cloughesy, Michael D. Prados, Brian Patrick O’Neill, Lauren E. Abrey, Tom Mikkelsen, Benjamin Purow, Roger Abounader, M. Kelly Nicholas and W.K. Alfred Yung and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

David Schiff

359 papers receiving 16.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

2009 1.9k citations Henry S. Friedman, Michael D. Prados et al. Journal of Clinical Oncology profile →
MicroRNA-34a Inhibits Glioblastoma Growth by Targeting Multiple Oncogenes

2009 515 citations Fadila Guessous, Charles G. diPierro et al. Cancer Research profile →
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review

2014 465 citations Thomas Kaley, David Schiff et al. profile →
Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

2011 401 citations Martin J. van den Bent, David Schiff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Schiff United States	69	8.0k	4.5k	3.8k	3.3k	3.0k	373	16.9k
Caterina Giannini United States	76	8.9k 1.1×	5.1k 1.1×	5.1k 1.3×	5.6k 1.7×	2.5k 0.8×	398	19.8k
Haley Gittleman United States	33	11.7k 1.5×	6.2k 1.4×	4.3k 1.1×	3.7k 1.1×	4.0k 1.3×	77	21.1k
Matthias Preusser Austria	69	6.9k 0.9×	4.2k 0.9×	5.8k 1.5×	2.6k 0.8×	2.3k 0.8×	543	18.4k
Tarık Tihan United States	57	6.2k 0.8×	3.4k 0.8×	2.5k 0.6×	3.2k 0.9×	1.5k 0.5×	255	13.4k
Kathleen R. Lamborn United States	81	12.8k 1.6×	5.1k 1.1×	5.6k 1.5×	3.0k 0.9×	3.1k 1.0×	292	22.7k
Ho‐Keung Ng Hong Kong	52	6.4k 0.8×	5.6k 1.2×	2.6k 0.7×	2.8k 0.9×	2.9k 1.0×	340	16.1k
Stuart A. Grossman United States	63	6.3k 0.8×	2.8k 0.6×	3.6k 0.9×	2.0k 0.6×	1.7k 0.6×	346	14.4k
Khê Hoang‐Xuan France	60	11.2k 1.4×	4.5k 1.0×	4.0k 1.0×	4.6k 1.4×	3.2k 1.1×	331	17.3k
Marc C. Chamberlain United States	66	10.9k 1.4×	2.3k 0.5×	7.4k 1.9×	4.2k 1.3×	1.7k 0.6×	329	17.9k
Roger Henriksson Sweden	52	5.5k 0.7×	4.8k 1.1×	3.7k 1.0×	1.6k 0.5×	2.8k 0.9×	405	14.7k

Countries citing papers authored by David Schiff

Since Specialization

Citations

This map shows the geographic impact of David Schiff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Schiff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Schiff more than expected).

Fields of papers citing papers by David Schiff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Schiff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Schiff. The network helps show where David Schiff may publish in the future.

Co-authorship network of co-authors of David Schiff

This figure shows the co-authorship network connecting the top 25 collaborators of David Schiff. A scholar is included among the top collaborators of David Schiff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Schiff. David Schiff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Patrie, James T., et al.. (2025). Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression. Journal of Neuro-Oncology. 175(3). 1147–1154.

Berr, Stuart S., et al.. (2024). An end-to-end deep learning pipeline to derive blood input with partial volume corrections for automated parametric brain PET mapping. Biomedical Physics & Engineering Express. 10(5). 55028–55028.

Galanis, Evanthia, S. Keith Anderson, Erin Twohy, et al.. (2022). Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances. 4(1). vdac041–vdac041. 6 indexed citations

Rudà, Roberta, David Capper, Adam Waldman, et al.. (2022). EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro-Oncology. 24(12). 2015–2034. 34 indexed citations

Schiff, David, Hans Messersmith, Priscilla K. Brastianos, et al.. (2022). Radiation Therapy for Brain Metastases: ASCO Guideline Endorsement of ASTRO Guideline. Journal of Clinical Oncology. 40(20). 2271–2276. 47 indexed citations

Mohile, Nimish, Hans Messersmith, Na Tosha Gatson, et al.. (2021). Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline. Neuro-Oncology. 24(3). 358–383. 12 indexed citations

Walbert, Tobias, Rebecca A. Harrison, David Schiff, et al.. (2021). SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro-Oncology. 23(11). 1835–1844. 80 indexed citations

Huang, Raymond Y., Robert J. Young, Benjamin M. Ellingson, et al.. (2020). Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro-Oncology. 22(12). 1822–1830. 26 indexed citations

Batchala, Prem P., James T. Patrie, Laila Poisson, et al.. (2020). Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes. American Journal of Neuroradiology. 41(5). 815–821. 11 indexed citations

10.

Galanis, Evanthia, S. Keith Anderson, Erin Twohy, et al.. (2019). A phase 1 and randomized, placebo‐controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 125(21). 3790–3800. 54 indexed citations

11.

Batchala, Prem P., Thomas Jose Eluvathingal Muttikkal, Joseph Donahue, et al.. (2019). Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas. American Journal of Neuroradiology. 40(3). 426–432. 62 indexed citations

12.

Patel, Sohil H., Anmol Bansal, Prem P. Batchala, et al.. (2019). Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype. American Journal of Neuroradiology. 40(7). 1149–1155. 70 indexed citations

13.

Cruickshanks, Nichola, Ying Zhang, Myron Gibert, et al.. (2018). Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clinical Cancer Research. 25(2). 663–673. 35 indexed citations

14.

Zhang, Ying, Nichola Cruickshanks, Fang Yuan, et al.. (2017). Targetable T-type Calcium Channels Drive Glioblastoma. Cancer Research. 77(13). 3479–3490. 81 indexed citations

15.

Braggio, Esteban, Scott Van Wier, Juhi Ojha, et al.. (2015). Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas. Clinical Cancer Research. 21(17). 3986–3994. 150 indexed citations

16.

Kim, Jungeun, Ying Zhang, Michael Skalski, et al.. (2014). microRNA-148a Is a Prognostic oncomiR That Targets MIG6 and BIM to Regulate EGFR and Apoptosis in Glioblastoma. Cancer Research. 74(5). 1541–1553. 105 indexed citations

17.

Zhang, Ying, Yanzhi Yang, Fadila Guessous, et al.. (2013). Hepatocyte Growth Factor Sensitizes Brain Tumors to c-MET Kinase Inhibition. Clinical Cancer Research. 19(6). 1433–1444. 29 indexed citations

18.

Guessous, Fadila, Yanzhi Yang, Elizabeth Johnson, et al.. (2011). Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy. Molecular Cancer Therapeutics. 11(2). 288–297. 19 indexed citations

19.

Friedman, Henry S., Michael D. Prados, Patrick Y. Wen, et al.. (2009). Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. Journal of Clinical Oncology. 27(28). 4733–4740. 1855 indexed citations breakdown →

20.

Li, Yunqing, Fadila Guessous, Manish Kumar, et al.. (2008). PTEN Has Tumor-Promoting Properties in the Setting of Gain-of-Function p53 Mutations. Cancer Research. 68(6). 1723–1731. 79 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact